Keulen Jibbe, Kemas Aurino, Youhanna Sonia, Shafagh Reza Zandi, Lauschke Volker M
Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
University of Tübingen, Tübingen, Germany.
Methods Mol Biol. 2025;2924:205-215. doi: 10.1007/978-1-0716-4530-7_14.
The drug development landscape is challenged by low success rates, largely due to the translational gap between effects observed in pre-clinical models and drug responses in clinical trials. Microphysiological systems (MPS) have the potential to narrow this gap by addressing some of the limitations of conventional static in vitro models, such as phenotypical irrelevance and lack of complexity. This is accomplished by integrating state-of-the-art microfluidics and bioengineering to better recapitulate tissue function and inter-organ crosstalk. Here, we describe the use of a multi-organ MPS for the culture of organotypic tissues. The system has been extensively optimized and benchmarked for assessing both short- and long-term dynamics and provides a low-absorption environment ideal for drug development.
药物研发面临着成功率低的挑战，这主要是由于临床前模型中观察到的效应与临床试验中的药物反应之间存在转化差距。微生理系统（MPS）有潜力通过解决传统静态体外模型的一些局限性来缩小这一差距，比如表型不相关性和缺乏复杂性。这是通过整合先进的微流体技术和生物工程技术来更好地模拟组织功能和器官间相互作用实现的。在此，我们描述了一种用于培养器官型组织的多器官MPS的应用。该系统已针对评估短期和长期动态变化进行了广泛优化和基准测试，并提供了一个适合药物研发的低吸收环境。
